91 related articles for article (PubMed ID: 1992325)
21. Graft-versus-leukemia without graft-versus-host disease: an elusive goal of bone marrow transplantation.
Champlin R
Semin Hematol; 1992 Jul; 29(3 Suppl 2):46-52. PubMed ID: 1509294
[No Abstract] [Full Text] [Related]
22. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
Azuma E; Yamamoto H; Kaplan J
J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
[TBL] [Abstract][Full Text] [Related]
23. Results of four different protocols for prophylaxis against graft-versus-host disease.
Tollemar J; Ringdén O; Bäckman L; Janossy G; Lönnqvist B; Markling L; Philstedt P; Sundberg B
Transplant Proc; 1989 Feb; 21(1 Pt 3):3008-10. PubMed ID: 2650414
[No Abstract] [Full Text] [Related]
24. Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantation.
Cao J; Chen C; Zeng L; Li L; Li Z; Xu K
Leuk Res; 2010 Oct; 34(10):1374-82. PubMed ID: 20018376
[TBL] [Abstract][Full Text] [Related]
25. Ultraviolet irradiation for the prevention of graft-versus-host disease and graft rejection in bone marrow transplantation.
Hudson JG; Lawler M; Pamphilon DH
Bone Marrow Transplant; 1994 Oct; 14(4):511-6. PubMed ID: 7858525
[TBL] [Abstract][Full Text] [Related]
26. [Acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation].
Kai S; Shinohara Y; Ifuku H; Ohe Y; Misawa M; Noguchi K; Kohsaki M; Kanamaru A; Hara H; Nagai K
Rinsho Ketsueki; 1985 Jan; 26(1):20-7. PubMed ID: 3889401
[No Abstract] [Full Text] [Related]
27. Graft-versus-host disease.
Vogelsang GB; Wagner JE
Hematol Oncol Clin North Am; 1990 Jun; 4(3):625-39. PubMed ID: 2193015
[TBL] [Abstract][Full Text] [Related]
28. [TNF-alpha in allogeneic bone marrow transplantation. Significance for immunologic reconstitution, acute graft versus host disease and risk of complications after bone marrow transplantation].
Holler E
Fortschr Med; 1991 Apr; 109(12):263-6. PubMed ID: 1855757
[TBL] [Abstract][Full Text] [Related]
29. [Control of graft-versus-host disease and infection associated with immunosuppression].
Teshima H; Masaoka T
Rinsho Ketsueki; 1991 Apr; 32(4):376-80. PubMed ID: 1906115
[TBL] [Abstract][Full Text] [Related]
30. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
Atkinson K; Downs K
Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: role of natural killer T cells.
Liu YP; Li Z; Nador RG; Strober S
Transplantation; 2008 Feb; 85(4):607-14. PubMed ID: 18347541
[TBL] [Abstract][Full Text] [Related]
32. Preparation of xenogeneic antibodies eliminating lymphocytes from human bone marrow selectively.
Wulff JC; Anderson M; Held H; Müller-Hermelink HK; Schlaak M; Müller-Ruchholtz W
Transplant Proc; 1981 Mar; 13(1 Pt 1):230-3. PubMed ID: 7022829
[No Abstract] [Full Text] [Related]
33. Cyclosporine-A as prevention for graft-versus-host disease in pediatric patients undergoing bone marrow transplants.
Truog AW; Wozniak SP
Oncol Nurs Forum; 1990; 17(1):39-44. PubMed ID: 2405360
[TBL] [Abstract][Full Text] [Related]
34. Prevention of graft-versus-host disease after bone marrow and small bowel transplantation by ultraviolet B modulation of bone marrow cells.
Chowdhury NC; Jin MX; Hardy MA; Oluwole SF
Transplant Proc; 1993 Feb; 25(1 Pt 1):475-6. PubMed ID: 8438384
[No Abstract] [Full Text] [Related]
35. T-cell-depleted autologous marrow fails to prevent acute graft-versus-host disease after allogeneic marrow transplantation for lymphoblastic lymphoma.
Przepiorka D; Giralt S; Huh YO; Andreeff M; Luna M; Reading C; Thomas M; Champlin RE
Transplant Proc; 1992 Dec; 24(6):2906-7. PubMed ID: 1465994
[No Abstract] [Full Text] [Related]
36. Unrelated bone marrow transplant. Use of IL2 receptor monoclonal antibody (IL2-R-Ab) in prophylaxis of GVHD. The GEGMO Group.
Belanger C; Esperou-Bourdeau H; Raffoux C; Gluckman E
Bone Marrow Transplant; 1991; 7 Suppl 2():122. PubMed ID: 1878669
[No Abstract] [Full Text] [Related]
37. A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts.
Henslee PJ; Byers VS; Jennings CD; Marciniak E; Thompson JS; Macdonald JS; Romond EH; Messino MJ; Scannon PJ
Transplant Proc; 1989 Feb; 21(1 Pt 3):3004-7. PubMed ID: 2650413
[No Abstract] [Full Text] [Related]
38. Unrelated donor bone marrow transplantation. Current concepts and future prospects.
Hows JM
Beitr Infusionsther; 1989; 24():172-9. PubMed ID: 2481535
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic bone marrow transplantation: relation between chimaerism and immunity.
Vossen J
Verh K Acad Geneeskd Belg; 1998; 60(2):111-43; discussion 143-5. PubMed ID: 9703764
[TBL] [Abstract][Full Text] [Related]
40. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
